Georges Gemayel
CIK 1256088 · Executive Chair of the Board · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GENZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BEDMINSTER, NJ 07921
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRON | Director | — | $79.69 | — | $0 | 5 | 2026-06-23 |
| SUPN | Director | 28,159 | $40.38 | $1.14M | -$2.35M | 22 | 2026-03-09 |
| Disc Medicine, Inc. (GMTX) Delisted | Executive Chair of the Board | — | $13.50 | — | $0 | 3 | 2022-01-05 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 0 | — | — | -$630.0K | 8 | 2020-10-01 |
| Dimension Therapeutics, Inc. (DMTX) Delisted | Director | — | — | — | $0 | 3 | 2017-11-07 |
| Raptor Pharmaceutical Corp (RPTP) Delisted | Director | 0 | — | — | $0 | 4 | 2016-10-26 |
| NPS PHARMACEUTICALS INC (NPSP) Delisted | Director | 0 | — | — | -$233.3K | 9 | 2015-02-24 |
| RPRX | Director | 1,852 | $62.13 | $115.1K | $0 | 5 | 2010-05-19 |
| Altus Pharmaceuticals Inc. (ALTU) Delisted | President & CEO | — | $10.12 | — | $0 | 4 | 2009-02-23 |
| GENZ | Executive Vice President | 14,090 | $38.48 | $542.2K | -$2.85M | 3 | 2007-11-02 |
Recent Filings · Page 5 of 8
75 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-15 | SUPN | Grant (A) | — | $0 | EDGAR |
| 2017-05-26 | Dimension Therapeutics, Inc. (DMTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-27 | SUPN | Grant (A) | — | $0 | EDGAR |
| 2016-10-26 | Raptor Pharmaceutical Corp (RPTP) Delisted | Mixed | −10,422 | -$93.8K | EDGAR |
| 2016-06-27 | Raptor Pharmaceutical Corp (RPTP) Delisted | Grant (A) | +8,330 | $0 | EDGAR |
| 2016-05-23 | Dimension Therapeutics, Inc. (DMTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-04-19 | Raptor Pharmaceutical Corp (RPTP) Delisted | Grant (A) | +2,092 | $0 | EDGAR |
| 2016-03-03 | SUPN | Grant (A) | — | $0 | EDGAR |
| 2016-01-05 | MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-03-24 | SUPN | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.